RhoVac's CEO, Anders Månsson, has tendered his resignation

RhoVac AB ("RhoVac"), announces today, July 15 2022, that the company's CEO, Anders Månsson, has announced his wish to leave his position with the company no later than after the 3-month stipulated notice period.

Pending a final decision regarding the company's future, RhoVac's CEO, Anders Månsson, has decided to give notice of termination of his employment with the company, and he will leave RhoVac no later than September 30.

Gunnar Gårdemyr, Chairman of the Board; “I wish Anders Månsson all the best in his new endeavours and sincerely thank him for his period as CEO of RhoVac. Anders did an excellent job, not least regarding the company's communication, both in success and adversity. We had a well-prepared exit process that could have been executed if only the crucial study, BRaVac, had reached its primary objective.”

Furthermore, the Board has not ruled out a possible merger with another company, in which case such a company will need to be headed by another CEO.

An Extraordinary General Meeting will be convened shortly to decide on the alternatives available to the company given the situation that has arisen after BRaVac.

This disclosure contains information that RhoVac is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 15-07-2022 10:12 CET.